[ET Net News Agency, 4 January 2022] Akeso, Inc. (09926) said Cadonilimab (PD-1/ CTLA-4
bi-specific antibody, research and development code: AK104), the world's first-in-class
novel immuno-oncology drug independently developed by the company, combined with
concurrent chemoradiotherapy obtained approval from the Center for Drug Evaluation (CDE)
of the National Medical Products Administration of the People's Republic of China to
initiate a phase III clinical trial for the treatment of locally advanced cervical cancer.
This is the first phase III clinical trial for locally advanced cervical cancer
immunotherapy in China. (RC)